Loading...
•
Jun 30, 2024
SpringWorks Therapeutics Q2 2024 Earnings Report
Reported second quarter financial results and recent business highlights.
Key Takeaways
SpringWorks Therapeutics reported a net product revenue of $40.2 million for OGSIVEO in the second quarter of 2024. The company completed the submission of its NDA for mirdametinib in NF1-PN. They also initiated a Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors.
Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter.
Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN.
Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting.
Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors.
Forward Guidance
The focus for the second half of 2024 will be to drive broader adoption of OGSIVEO, to advance commercial preparations for the launch of mirdametinib for children and adults with NF1-PN, to continue advancing OGSIVEO and mirdametinib through the European regulatory process, and to progress the emerging portfolio for patient populations with high unmet needs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...